MARTINSRIED and MUNICH, Germany, Dec. 11 /PRNewswire/ -- MorphoSys AG (Neuer Markte: MOR), Munich/Germany today announced the achievement of the first milestone in their collaboration with Roche on HuCAL-derived medications for the treatment of Alzheimer's Disease. This achievement triggers an undisclosed milestone payment from Roche to MorphoSys.
Under the agreement, which was made public September 11, 2000, MorphoSys' HuCAL-Fab library is being used to generate and to optimise antibodies to the Roche biological target. Roche will be responsible for the clinical development, regulatory approval, and worldwide marketing of any resulting products.
``We are extremely happy to reach the first milestone within two months of starting work'', commented Dr. Thomas von Rueden, Chief Scientific Officer, MorphoSys AG. ``We are looking forward to further promising results of this collaboration.''.... |
